← All Beigene, LTD filings

Beigene, LTD Schedule 13D activist filings

Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.

BGNE
Beigene, LTD
SCHEDULE: Baker Bros. Advisors LP Secures Financing for BeOne Medicines
Baker Bros. Advisors LP has entered into revolving note agreements to finance the exercise of employee stock options for BeOne Medicines Ltd. ADS.
BGNE
Beigene, LTD
SCHEDULE: Baker Bros. Advisors Increases BeOne Medicines Stake
Baker Bros. Advisors LP and affiliated entities have amended their Schedule 13D filing, reporting a combined beneficial ownership of approximately 8.0% of BeOne Medicines Ltd. ordinary shares following a board appointment.
BGNE
Beigene, LTD
SCHEDULE: Baker Bros. Advisors Updates BeOne Medicines Stake
Baker Bros. Advisors filed an amendment to their Schedule 13D regarding their 8.0% beneficial ownership in BeOne Medicines Ltd.
BGNE
Beigene, LTD
SCHEDULE 13D/A: Hillhouse Funds Significantly Reduce BeiGene Stake, File Final Exit Amendment
HHLR Advisors and Hillhouse Investment Management have filed their final Schedule 13D amendment, disclosing a significant reduction in their beneficial ownership of BeiGene, Ltd. ordinary shares to 4.9% following a recent block trade.
BGNE
Beigene, LTD
SCHEDULE 13D/A: Hillhouse Affiliates Reduce BeiGene Stake Through Significant ADS Sale
HHLR Advisors and Hillhouse Investment Management, affiliates under common control, have reduced their beneficial ownership in BeiGene, Ltd. to 6.7% following the sale of 2.48 million American Depositary Shares.